Popular on TelAve
- Texas Center For Oral Surgery & Dental Implants Launches Redesigned Website to Enhance Patient Experience
- Nola Blue Records signs legendary Maria Muldaur and estimable Candice Ivory
- New Age of Law Firm Website Design
- OmegaBrand Introduces New Thermal Transfer Ribbons for Honeywell PC45t Printers
- Stan Fitzgerald: A Profile in Resilience and Leadership with VFAF Veterans for America First Organizational Support for a Presidential Pardon
- New Drug Application to the FDA for the Treatment of Suicidal Depression that Affects 13+ Million Americans Each Year: NRx Pharma: Stock Symbol:NRXP
- PRP Aviation Earns Prestigious "Platinum Cirrus Training Center" Designation
- New Year's Eve Austin Uber credit for first 500 people courtesy of Byrd Davis Alden & Henrichson
- Cyntexa Joins the ServiceNow Consulting and Implementation Partner Program to Envision, Build, and Deploy Meaningful Experiences
- Acquisition of Kadima Neuropsychiatry Institute for CNS & Psychedelic Research Planned; New Drug Application for Suicidal Depression Treatment: $NRXP
Similar on TelAve
- OneSolution® Dental Implant Centers Celebrates Over 15,000 Successful Full-Arch Cases
- SlotCycle Raises $5.6M to Transform Secondary Gaming Equipment Market, Led by Discerning Capital
- AI Technology Advances in 2025, Fully Automated Solutions Reach the Investment World
- Los Angeles Fires: Supporting Recovery Without Psychotropic Drug Risks
- New Middle East Partnership for up to $40 Million Supporting Entry Into Emerging Global MOBA Digital Game Arena: NIP Group (Stock Symbol: NIPG)
- Profitable Exciting New Entry Into Emerging Global MOBA Digital Game Arena, Plus New Strategic Partnership with The9 Limited: NIP Group; Stock: NIPG
- Momentum Stock Trading: AI-Driven by Tickeron
- Dr. Lauren Anderson Led a Successful CE Event: Digital Planning and Execution
- Latest Updates to Pennsylvania Medical Malpractice and Birth Injury Law
- CCHR Cites Newly Released Mind Control Records to Oppose Psychedelics
AI Team from "PersonalAIze" Expert Assessment; Groundbreaking AI Platform Starting with Early Cancer Detection: Renovaro; Stock Symbol: RENB
TelAve News/10840857
PersonalAIze, a cutting-edge company in AI and machine learning applications for healthcare, has conducted a comprehensive evaluation of the RENB RenovaroCube's advanced AI platform.
AMSTERDAM - TelAve -- Renovaro, Inc. (Stock Symbol: RENB) aims to accelerate precision and personalized medicine for longevity powered by mutually reinforcing AI and biotechnology platforms for early diagnosis, better-targeted treatments, and drug discovery. RENB includes RenovaroBio with its advanced cell-gene immunotherapy company and RenovaroCube.
RENB RenovaroCube has developed an award-winning AI platform that is committed to the early detection of cancer and its recurrence and monitoring subsequent treatments. RenovaroCube intervenes at a stage where potential therapy can be most effective.
RENB RenovaroCube is a molecular data science company with a background in FinTech and a 12-year history. It brings together proprietary artificial intelligence (AI) technology, multi-omics, multi-modal data, and the expertise of a carefully selected multidisciplinary team to radically accelerate precision medicine and enable breakthrough changes in cancer care.
Independent Expert Assessment Validates RENB RenovaroCube's Potential as a Groundbreaking AI Platform Starting with Early Cancer Detection
Assessment by specialist AI team from "PersonalAIze" Highlights the Strength, Potential, and Visionary Talent Behind the Innovative Software as a Service (SaaS) Platform
PersonalAIze, a cutting-edge company in AI and machine learning applications for healthcare, has conducted a comprehensive evaluation of the RENB RenovaroCube's advanced AI platform. This effort is spearheaded by PersonalAIze CEOs and AI experts, Mark Hoogendoorn and Sandjai Bhulai, who bring their extensive expertise to assess the platform developed under the guidance of Frank van Asch, CTO and co-Founder of the technology on which the RENB RenovaroCube is based.
More on TelAve News
The RENB RenovaroCube AI platform has been advancing innovation for the past 12 years, evolving from its award-winning Fintech roots into a potentially groundbreaking multi-omic molecular differential system that identifies cancer in its earliest stages. It is an open platform that can be used as a SaaS by many private sector and academic or other large hospital and health systems. It is also disease agnostic, so it can be expanded for many purposes.
The initial aim for RENB is to transform cancer early detection and early detection of recurrence from a small vial of blood (liquid biopsy), potentially supporting clinicians to initiate treatments as soon as possible towards improved outcomes for patients.
Based on these findings, PersonalAIze is eager to collaborate further with RENB RenovaroCube to enhance and commercialize the platform.
This partnership for RENB could represent a substantial step forward in the fight against cancer, bringing together AI innovation and healthcare expertise to develop a powerful tool for early detection that has the potential to save countless lives.
RENB RenovaroCube Presented Cutting-Edge Cancer Diagnostics Research at European Society for Medical Oncology Congress
RENB has presented two scientific presentations at a leading cancer conference – the European Society for Medical Oncology (ESMO) Congress – on September 15, 2024.
One RENB presentation describes the development of a deep learning model that leverages cell-free DNA (cfDNA) fragmentation features (fragmentomics) from a small sample of blood to detect cancer. The results show that in comparison to state-of-the-art cfDNA cancer detection models, we were able to perform on par while utilizing only minute amounts of genetic data. The integration of fragmentomics into the Cube's current platform, further enhances its capacity to detect cancer, potentially leading to earlier and/or better treatment options and improved patient outcomes.
More on TelAve News
A second RENB study demonstrated the Cube platform's ability to correlate methylation patterns from cancer tissue in cfDNA derived from plasma, indicating that cancer can be detected in blood samples as an alternative for invasive tissue biopsies.
To Review $RENB visit: http://www.renovarobio.com and https://compasslivemedia.com/renb/
Media Contact
Company Name: Renovaro Inc.
Contact Person: The Hon. Mark Dybul, MD, CEO
Company Websites: www.renovarobio.com
Email: ir@renovarobio.com
Phone: 732-780-5036
Home Country: United States
DISCLAIMER: https://corporateads.com/disclaimer/
Disclosure listed on the CorporateAds website
RENB RenovaroCube has developed an award-winning AI platform that is committed to the early detection of cancer and its recurrence and monitoring subsequent treatments. RenovaroCube intervenes at a stage where potential therapy can be most effective.
RENB RenovaroCube is a molecular data science company with a background in FinTech and a 12-year history. It brings together proprietary artificial intelligence (AI) technology, multi-omics, multi-modal data, and the expertise of a carefully selected multidisciplinary team to radically accelerate precision medicine and enable breakthrough changes in cancer care.
Independent Expert Assessment Validates RENB RenovaroCube's Potential as a Groundbreaking AI Platform Starting with Early Cancer Detection
Assessment by specialist AI team from "PersonalAIze" Highlights the Strength, Potential, and Visionary Talent Behind the Innovative Software as a Service (SaaS) Platform
PersonalAIze, a cutting-edge company in AI and machine learning applications for healthcare, has conducted a comprehensive evaluation of the RENB RenovaroCube's advanced AI platform. This effort is spearheaded by PersonalAIze CEOs and AI experts, Mark Hoogendoorn and Sandjai Bhulai, who bring their extensive expertise to assess the platform developed under the guidance of Frank van Asch, CTO and co-Founder of the technology on which the RENB RenovaroCube is based.
More on TelAve News
- Des Moines Home Buyers, LLC: Trusted Professionals Offering Cash for Houses Since 2006
- K2 Integrity Appoints Jason Straight as Senior Managing Director for Cyber Resilience and Digital Risk Advisory Practice
- 7 years ago a vision was born. Today 700+ clients are thriving with Cyntexa's expertise
- Infinity Garage Door Repair Offers 24/7 Emergency Service & Smart Home Upgrades in Las Vegas
- SlotCycle Raises $5.6M to Transform Secondary Gaming Equipment Market, Led by Discerning Capital
The RENB RenovaroCube AI platform has been advancing innovation for the past 12 years, evolving from its award-winning Fintech roots into a potentially groundbreaking multi-omic molecular differential system that identifies cancer in its earliest stages. It is an open platform that can be used as a SaaS by many private sector and academic or other large hospital and health systems. It is also disease agnostic, so it can be expanded for many purposes.
The initial aim for RENB is to transform cancer early detection and early detection of recurrence from a small vial of blood (liquid biopsy), potentially supporting clinicians to initiate treatments as soon as possible towards improved outcomes for patients.
Based on these findings, PersonalAIze is eager to collaborate further with RENB RenovaroCube to enhance and commercialize the platform.
This partnership for RENB could represent a substantial step forward in the fight against cancer, bringing together AI innovation and healthcare expertise to develop a powerful tool for early detection that has the potential to save countless lives.
RENB RenovaroCube Presented Cutting-Edge Cancer Diagnostics Research at European Society for Medical Oncology Congress
RENB has presented two scientific presentations at a leading cancer conference – the European Society for Medical Oncology (ESMO) Congress – on September 15, 2024.
One RENB presentation describes the development of a deep learning model that leverages cell-free DNA (cfDNA) fragmentation features (fragmentomics) from a small sample of blood to detect cancer. The results show that in comparison to state-of-the-art cfDNA cancer detection models, we were able to perform on par while utilizing only minute amounts of genetic data. The integration of fragmentomics into the Cube's current platform, further enhances its capacity to detect cancer, potentially leading to earlier and/or better treatment options and improved patient outcomes.
More on TelAve News
- Integris Composites Debuts its Concealed Response Shield System; 'Situational Armor' for Active-Shooter Responders When Seconds Count
- FOLKS Expands With The Launch Of FOLKS USA
- Safe Night Partners With Simsi To Offer A New Certification For Proactive Alliance With Rutgers University
- AI Technology Advances in 2025, Fully Automated Solutions Reach the Investment World
- The One Experience™, Inc. Announces Inspiring Lineup of Pathway Guides for The One 2025 Event
A second RENB study demonstrated the Cube platform's ability to correlate methylation patterns from cancer tissue in cfDNA derived from plasma, indicating that cancer can be detected in blood samples as an alternative for invasive tissue biopsies.
To Review $RENB visit: http://www.renovarobio.com and https://compasslivemedia.com/renb/
Media Contact
Company Name: Renovaro Inc.
Contact Person: The Hon. Mark Dybul, MD, CEO
Company Websites: www.renovarobio.com
Email: ir@renovarobio.com
Phone: 732-780-5036
Home Country: United States
DISCLAIMER: https://corporateads.com/disclaimer/
Disclosure listed on the CorporateAds website
Source: Corporate Ads
0 Comments
Latest on TelAve News
- Biz To Biz Palm Beach Business Trade Expo
- Profitable Exciting New Entry Into Emerging Global MOBA Digital Game Arena, Plus New Strategic Partnership with The9 Limited: NIP Group; Stock: NIPG
- A Historic Night Awaits: RNHA Celebrating the Power of the Latino Vote at Inauguration 2025
- Namebadges.com Expands Shipping Services to Mexico and Canada
- Keells Leverages Cyntexa and Salesforce to Redefine Customer Loyalty with Digital Innovation
- PhaseZero Releases CxCommerce™ 7.0 with Proven Scale for the Largest Enterprises and Affordability for Small Businesses
- Century Fasteners Corp. Mourns the Loss of Colleague and Friend, Mark James
- COLORICH PACKAGING Will Participate in the COSME Week 2025 TOKYO and Cosmoprof Worldwide Bologna 2025 Exhibition
- IntellaTriage Launches New Patient Engagement Service
- Momentum Stock Trading: AI-Driven by Tickeron
- IntellaTriage Launches New Patient Engagement Service
- Cascadia Global Security Launches Cascadia Off-Duty
- Anti-Racism Song from Neal Fox Drops in Time for Martin Luther King Day
- Genpak Expands Foodservice Packaging to Include Durable, Polypropylene Bowls
- DayPass Expands to 50 New Destinations in 2024, Bringing Luxury Day Experiences to Travelers and Locals
- Dr. Lauren Anderson Led a Successful CE Event: Digital Planning and Execution
- "One World in a New World" Amplifies Voices of Transformation, Resilience, and Global Connection
- WalkerHughes Insurance Expands Footprint With Acquisition of Independent Brokers Agency LLC
- Hawk Tuah VIP Shop launches Exclusive Merchandise line for Viral Meme Fans
- Orcas Island Property Owner Returns Two Prime Waterfront Properties to the Market